Can I read Outcomes Associated with Immune-related Adverse Events in Metastatic Non-small Cell Lung Cancer Treated with Nivolumab: a Pooled Exploratory Analysis from a Global Cohort on EtoBox?

Outcomes Associated with Immune-related Adverse Events in Metastatic Non-small Cell Lung Cancer Treated with Nivolumab: a Pooled Exploratory Analysis from a Global Cohort by Abdul Rafeh Naqash; Biagio Ricciuti; Dwight H. Owen; Vaia Florou; Yukihiro Toi; Cynthia Cherry; Maida Hafiz; Andrea De Giglio; Mavish Muzaffar; Sandip H. Patel; Shunichi Sugawara; Jarred Burkart; Wungki Park; Rita Chiari; Jun Sugisaka; Gregory A. Otterson; Gilberto de Lima Lopes; Paul R. Walker is a Immunology and Microbiology article available to read on EtoBox.

What is Outcomes Associated with Immune-related Adverse Events in Metastatic Non-small Cell Lung Cancer Treated with Nivolumab: a Pooled Exploratory Analysis from a Global Cohort about?

Background Immune-related adverse events (irAEs) comprise a distinct spectrum of auto-inflammatory manifestations triggered due to immune checkpoint inhibitors (ICI). Current data on the association of irAEs with outcomes in NSCLC treated with nivolumab are limited. Methods and objectives We pooled data from 531 metastatic NSCLC patients from five centers treated with nivolumab after failing platinum-based chemotherapy. The primary objective was to investigate the relationship between irAEs with clinical benefit to nivolumab as well as to elucidate patterns of irAE-related ICI discontinuations and their impact on survival. Results 33.0% (173/531) of patients treated with nivolumab were noted to have an irAE. Patients with irAEs had a significantly longer median PFS [6.1 vs. 3.1 months, HR 0.68 95% CI (0.55-0.85); p = 0.001] and OS [14.9 vs. 7.4 months, HR 0.66 95% CI (0.52-0.82); p < 0.001)] compared to those without irAEs. In multivariate analysis, the presence of irAEs showed a significantly better PFS [HR 0.69, 95% CI (0.55-0.87); p = 0.002] and a trend for better OS [HR 0.62, 95% CI (0.55-1.03); p = 0.057]. Patients with permanent ICI discontinuation secondary to index irAE had

Who reads Outcomes Associated with Immune-related Adverse Events in Metastatic Non-small Cell Lung Cancer Treated with Nivolumab: a Pooled Exploratory Analysis from a Global Cohort?

Author

Abdul Rafeh Naqash; Biagio Ricciuti; Dwight H. Owen; Vaia Florou; Yukihiro Toi; Cynthia Cherry; Maida Hafiz; Andrea De Giglio; Mavish Muzaffar; Sandip H. Patel; Shunichi Sugawara; Jarred Burkart; Wungki Park; Rita Chiari; Jun Sugisaka; Gregory A. Otterson; Gilberto de Lima Lopes; Paul R. Walker

Publisher

Springer Science and Business Media LLC

Published

2020

Language

EN

Field

Immunology and Microbiology (Life Sciences)